Clinical trials: Chronic Pulmonary Obstruction
Chronic Obstructive Pulmonary Disease
Oxis 9mcg Turbuhaler Clinical Experience Investigation
The purpose of the investigation is to confirm the ADR development and the contributing factors possibly having an impact on the safety under the post-marketing actual use of Oxis 9 mcg Turbuhaler.
- Trial name
- NCT01749462
- Where
- 41 sites in Japan
- Volunteers
- 398 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study assessed the effect of QVA149 on patient-reported dyspnea in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) patients.
- Trial name
- BLAZE (NCT01490125)
- Testing
- QVA149, Tiotropium, Salbutamol/albuterol
- Where
- 43 sites in Belgium, Canada and 3 more
- Volunteers
- 247 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period.
- Trial name
- NCT01040689
- Testing
- Olodaterol (BI1744) Low, Olodaterol (BI1744) High, Tiotropium 18 mcg
- Where
- 15 sites in Belgium, Denmark and 2 more
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
The purpose of the study is to determine the efficacy and safety of the combination of ADVAIR DISKUS® 250/50mcg (FLUTICASONE PROPIONATE/SALMETEROL COMBINATION PRODUCT) plus SPIRIVA® HANDIHALER® inhaler 18mcg (TIOTROPIUM) compared…
- Trial name
- ADC111114 (NCT00784550)
- Testing
- Tiotropium Bromide, Fluticasone Propionate/Salmeterol
- Where
- 35 sites in United States
- Volunteers
- 342 people
- Sponsor
- GlaxoSmithKline
Acute Respiratory Distress Syndrome (ARDS), Pneumonia
Medical Device Clinical Trial Without CE Marking to Evidence Safety and Performance of the INBENTUS VERSATILE Ventilator in Patients Requiring Assisted/Controlled Mechanical Ventilation and Weaning.
Pre-market clinical trial on 81 aldults participants to evidence safety and performance of the non-CE-marked medical device INBENTUS VERSATILE ventilator.
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), Pneumonia, COPD (Chronic Obstructive Pulmonary Disease), Postoperative Respiratory Distress
- Trial name
- NCT07432191
- Testing
- INBENTUS VERSATILE
- Where
- Spain
- Volunteers
- 81 people
- Sponsor
- Iconic Solutions By Murcia SL
Pulmonary Disease, Chronic Obstructive
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
The primary objective of this study is to compare the bronchodilator efficacy of three doses (50 µg, 100 µg and 200 µg) of BEA 2180 delivered by the Respimat® once daily to placebo and tiotropium bromide delivered by the…
- Trial name
- NCT00528996
- Testing
- BEA 2180 BR, Tiotropium Bromide
- Where
- 178 sites in United States, Canada and 8 more
- Volunteers
- 2,080 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
To evaluate the efficacy of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT07147946
- Testing
- TQC3721 Suspension for inhalation
- Where
- 76 sites in China
- Volunteers
- 666 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination
The objective is to provide data supporting the use of LAS40464 as an efficacious and safe maintenance bronchodilator treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT01462942
- Testing
- Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate
- Where
- 197 sites in Austria, Belgium and 20 more
- Volunteers
- 2,443 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat Inhaler
The objectives were to collect information on vital status and pulmonary medication use at the predicted exit date for patients who participated in two one-year trials and withdrew prematurely.
- Trial name
- NCT02172560
- Testing
- Tiotropium
- Where
- 19 sites in Australia, New Zealand and 1 more
- Volunteers
- 441 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease
To obtain further information on the tolerability and efficacy of Atrovent® 500µg/2ml inhalation solution in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Trial name
- NCT02238197
- Testing
- Atrovent® Inhalation Solution
- Volunteers
- 477 people
- Sponsor
- Boehringer Ingelheim
Respiratory Disease, Asthma
Digital App for Telerehabilitation in Respiratory Diseases
The purpose of this study is to evaluate the feasibility and the mid-term effects of a pulmonary rehabilitation intervention, delivered by digital App, on quality of life of patients affected by respiratory diseases.
- Conditions
- Respiratory Disease, Asthma, Long COVID, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05572346
- Testing
- Home-based telerehabilitation program delivered through digital devices
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- MedicAir Healthcare S.r.l.
Pulmonary Emphysema
Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation
The purpose of this study is to determine the effective dose of the Aeris BLVR System in patients with advanced emphysema.
- Trial name
- NCT00205920
- Testing
- BLVR Hydrogel
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Aeris Therapeutics
Chronic Obstructive Pulmonary Disease (COPD)
Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients
This study compared the correct use of and patient preference for two drug delivery systems (inhalers) in patients with COPD
- Trial name
- INHALATOR (NCT01727024)
- Testing
- Tiotropium, Indacaterol
- Where
- 10 sites in Brazil
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block
The objective of this pivotal study is to evaluate the relative bioavailability of Synflutide HFA 250/25 Inhaler and SeretideTM 250 EvohalerTM in healthy volunteers with charcoal block.
- Trial name
- NCT02466503
- Testing
- Fluticasone propionate, Salmeterol (as xinafoate)
- Where
- Taiwan
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Intech Biopharm Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
Tezepelumab COPD Exacerbation Study
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- COURSE (NCT04039113)
- Testing
- Tezepelumab
- Where
- 91 sites in United States, Canada and 8 more
- Volunteers
- 337 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease
The primary objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.
- Trial name
- NCT06099652
- Testing
- 611 300 mg Q2W, 611 450 mg Q2W
- Where
- 3 sites in China
- Volunteers
- 142 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
COPD (Chronic Obstructive Pulmonary Disease)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD
To evaluate the efficacy and safety of a 12-week administration of HSK39004 inhalation powder in clinical trial participants with COPD
- Trial name
- NCT07583849
- Testing
- HSK39004 Dry Powder Inhaler Simulant, HSK39004 Dry Powder Inhaler-0.75mg
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
COPD
A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease
The purpose of this study is to investigate 5 doses of RPL554 and placebo, administered by pressurized metered dose inhaler (pMDI), in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT04091360
- Testing
- Part A: RPL554, Part B: RPL554
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Asthma
The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma
The objective of this study is to evaluate fluticasone furoate/vilanterol compared with fluticasone furoate alone in subjects with asthma that is uncontrolled on low to mid dose inhaled corticosteroid (ICS) or low dose ICS/ long…
- Trial name
- NCT03363191
- Testing
- Fluticasone Furoate/Vilanterol, Fluticasone Furoate, Salbutamol/Albuterol
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Characterisation of People With COPD
The investigators will describe the characteristics, prevalence, incidence, severity co-morbidity and management of patients with chronic obstructive pulmonary disease (COPD) in the UK.
- Trial name
- CoCO (NCT01263340)
- Where
- United Kingdom
- Volunteers
- 10,000 people
- Sponsor
- National Services for Health Improvement Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.